Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-37635 AXSOME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 45-4241 ...

Table of Contents | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Axsome Therapeutics (NASDAQ:AXSM) Q4 2018 Earnings Conference Call March 14, 2019 8:00 AM ET Company Participants Mark Jacobson - Senior Vice President, Operations Herriot Tabuteau - Chief Executive Officer Cedric O’Gorman - Senior Vice President, Clinical Development and Medical Affairs Nick Pizzie - Chief Financial Officer Conference Call Participants Matt Kaplan - Ladenburg Thalmann Bert Hazlett - BTIG Charles Duncan - Cantor Ram Selvaraju - H.C. Wainwright Operator Good morning, ladies and gentlemen and ...